Kindred biosciences, inc. (KIN)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
Net product revenues

4,344

4,256

3,495

2,391

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from Contract with Customer, Including Assessed Tax

-

-

-

-

-

1,966

-

-

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating costs and expenses:
Cost of product revenues

4,072

587

614

585

416

324

110

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

30,025

28,310

28,932

29,119

28,205

26,399

23,785

21,185

19,231

17,665

16,032

14,909

14,204

13,861

14,931

16,210

18,040

19,412

19,635

18,357

19,005

18,694

15,638

12,836

7,497

3,140

1,469

0

0

0

Selling, general and administrative

-

-

0

0

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

0

0

-

-

0

26,499

-

-

-

13,988

11,569

10,322

9,131

8,308

7,788

7,861

7,917

7,850

7,983

8,230

8,813

8,539

7,166

5,083

2,675

1,079

483

0

0

0

Restructuring costs

0

-

-

-

0

-

-

-

-

-

-

-

-

655

655

655

655

0

0

0

0

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

-

-

67,113

64,497

-

53,222

45,995

39,946

35,278

31,653

27,601

25,231

23,335

22,824

23,374

24,726

26,612

27,262

27,618

26,587

27,818

27,233

22,804

17,919

10,172

4,219

1,952

0

0

0

Loss from operations

-68,327

-62,567

-62,932

-60,780

-57,638

-51,256

-45,355

-39,946

-35,278

-31,653

-27,601

-25,231

-23,335

-22,824

-23,374

-24,726

-26,612

-27,262

-27,618

-26,587

-27,818

-27,233

-22,804

-17,919

-10,172

-4,219

-1,952

0

0

0

Interest and other (expense) income, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

-

1,178

1,836

1,940

-

1,566

1,376

1,114

920

774

643

480

404

325

264

204

154

132

0

0

0

-

-

-

-

-

-

-

-

-

Interest and other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94

71

48

15

6

2

0

0

0

Net loss

-68,095

-61,389

-61,096

-58,840

-55,774

-49,690

-43,979

-38,832

-34,358

-30,879

-26,958

-24,751

-22,931

-22,499

-23,110

-24,522

-26,458

-27,130

-27,499

-26,476

-27,703

-27,139

-22,733

-17,871

-10,157

-4,213

-1,950

0

0

0

Change in unrealized gains or losses on available-for-sale securities

-17

-24

-31

-38

-29

-20

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized gains or losses on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Comprehensive loss

-68,078

-61,365

-61,065

-58,802

-55,745

-49,670

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss per share, basic and diluted (in usd per share)

-0.58

-0.40

-0.39

-0.37

-0.42

-0.46

-0.39

-0.39

-0.36

-0.35

-0.29

-0.29

-0.30

-0.29

-0.29

-0.25

-0.31

-0.32

-0.36

-0.35

-0.34

-0.34

-0.31

-0.42

-0.38

-0.40

-0.40

-0.13

-0.07

-0.06

Weighted-average number of common shares outstanding, basic and diluted (in shares)

39,186

38,999

38,940

38,887

37,786

33,708

33,601

28,619

27,986

27,915

27,400

23,409

21,516

19,900

19,891

19,865

19,836

19,816

19,792

19,756

19,726

19,719

19,713

19,426

16,222

5,899

3,005

3,000

3,000

2,113